Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05229991
Registration number
NCT05229991
Ethics application status
Date submitted
27/01/2022
Date registered
8/02/2022
Date last updated
6/05/2023
Titles & IDs
Public title
Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection
Query!
Scientific title
Once Daily (QD) Dosing of Lonafarnib (LNF) Co-administered With Ritonavir (RTV) for Treatment of Chronic Hepatitis D Virus Infection
Query!
Secondary ID [1]
0
0
SCRC20042
Query!
Secondary ID [2]
0
0
SOR-0527-20-CTIL
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
LOWR6
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Hepatitis D, Chronic
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Lonafarnib
Treatment: Drugs - Ritonavir
Experimental: Intervention Group - Lonafarnib 50mg co-administered with ritonavir 200 mg
Treatment: Drugs: Lonafarnib
once-daily dosing of lonafarnib 50 mg with ritonavir 200 mg over a 48-week treatment period.
Treatment: Drugs: Ritonavir
once-daily dosing of lonafarnib 50 mg with ritonavir 200 mg over a 48-week treatment period.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Viral load change
Query!
Assessment method [1]
0
0
Change from baseline in HDV viral load at end of treatment
Query!
Timepoint [1]
0
0
48 weeks
Query!
Primary outcome [2]
0
0
Viral load change
Query!
Assessment method [2]
0
0
Change from baseline in HDV viral load at end of follow-up
Query!
Timepoint [2]
0
0
72 weeks
Query!
Secondary outcome [1]
0
0
HDV RNA levels below LLOQ
Query!
Assessment method [1]
0
0
Proportion of patients with HDV RNA levels below limit of quantification (LLOQ) at end of treatment and end of follow up
Query!
Timepoint [1]
0
0
72 weeks
Query!
Secondary outcome [2]
0
0
Viral load change
Query!
Assessment method [2]
0
0
Change from baseline in HDV viral load at weeks 4, 12 and 24
Query!
Timepoint [2]
0
0
24 weeks
Query!
Eligibility
Key inclusion criteria
1. Chronic HDV infection, with compensated liver disease, documented by a positive HDV
antibody (Ab) test and HDV RNA by quantitative polymerase chain reaction (qPCR) assay,
prior to initiation of trial treatment.
2. Demonstrable suppression of HBV DNA (< 100 IU/mL) following anti-HBV nucleos(t)ide
treatment prior to initiating trial therapy.
3. Willing and able to comply with trial procedures and provide written informed consent.
4. ALT > ULN documented on at least one occasion during the 12 months preceding
enrollment to the trial.
5. Male and female participants who are 18 years of age or above.
6. ECGs demonstrating no acute ischemia or clinically significant (CS) abnormality and a
corrected QT interval by Fridericia correction formula (QTcF) < 450 ms in males and
<470 ms in females.
7. Sexually active female patients of childbearing potential and sexually active male
patients with partners of childbearing potential must agree to use adequate methods of
contraception during the trial. Females of childbearing potential are all those except
women who are surgically sterile, who have medically documented ovarian failure, or
who are at least 1 year postmenopausal.
For female patients:
- Progestin-based hormonal contraception (implant, injection, oral) associated with
inhibition of ovulation for = 3 months before screening. Use of a progestin-based
implant or injection method requires the additional use of a barrier method (use of
condom [male partner] or diaphragm with spermicide or cervical cap with spermicide)
from screening. Use of a progestin-only, oral method requires the additional use of
double barrier methods (use of condom [male partner] with either diaphragm with
spermicide or cervical cap with spermicide) from screening, or
- Intrauterine device (IUD) or intrauterine system (IUS) in place = 3 months before
screening AND a barrier method (use of condom [male partner] or diaphragm with
spermicide or cervical cap with spermicide) from screening, or
- Surgical sterilization of the partner (vasectomy = 1 month before screening) AND a
barrier method (use of condom [male partner] or diaphragm with spermicide or cervical
cap with spermicide) from screening, or
- Double-barrier methods (use of condom [male partner] with either diaphragm with
spermicide or cervical cap with spermicide) from screening.
For male patients:
- Surgical sterilization (vasectomy = 1 month before screening) AND a barrier method
(use of condom or diaphragm with spermicide or cervical cap with spermicide) from
screening, or
- Consistently and correctly use a condom from screening AND female partner must agree
to use a hormonal contraceptive, a nonhormonal non-barrier method (eg, copper IUD), or
a nonhormonal barrier method (eg, diaphragm with spermicide or cervical cap with
spermicide).
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Participation in a clinical trial with, or use of, any investigational agent within 30
days or 5 half-lives, whichever is longer, before starting LNF treatment.
2. Female patients who are pregnant or breastfeeding. Female patients must have a
negative serum test at screening and a negative urine pregnancy test (minimum
sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [hCG] at
baseline, within 24 hours prior to the start of any investigational agent). Male
patients with female sexual partners who are pregnant.
3. Current or previous history of decompensated liver disease (e.g. variceal bleeding,
ascites, hepatic encephalopathy, hepatorenal syndrome).
4. Platelet count < 70,000 cells/mm3; white blood cell (WBC) < 3,000 cells / mm3
5. Creatinine clearance (< 30 mL/min by Cockroft-Gault).
6. Co-infected with human immunodeficiency virus (HIV) or hepatitis C virus (HCV).
Patients with a positive HCV Ab at baseline are allowed if they have completed a
curative antiviral regimen and have documented undetectable HCV RNA 12 weeks or more
following last dose of anti-HCV medications.
7. Abnormal thyroid-stimulating hormone (TSH) or free thyroxine (fT4) levels. Patients
with well-controlled thyroid function or TFTs that are not clinically significant may
be enrolled.
8. Evidence of another form of viral hepatitis or another form of liver disease (eg,
autoimmune liver disease, primary biliary cirrhosis, primary sclerosing cholangitis,
Wilson's disease, alcoholic liver disease, nonalcoholic steatohepatitis,
hemochromatosis, alpha 1 anti-trypsin deficiency).
9. History of hepatocellular carcinoma.
10. Retinal disorder or clinically relevant ophthalmic disorder
11. Any malignancy within 5 preceding years. Exceptions are malignancies surgically
excised with curative intent and/or evidence of being disease free for at least 5
years (eg, breast ductal carcinoma in situ [DCIS] or squamous/basal cell skin cancer
treated with curative intent), or successfully treated in-situ carcinoma of the cervix
12. Other significant medical condition that may require intervention during the trial.
13. Any condition that may impact proper absorption (eg, short bowel syndrome,
inflammatory bowel disease, atrophic gastritis, partial gastrectomy) should be
discussed with the Medical Monitor.
14. Consumption of grapefruit, Seville oranges, or product that contains grapefruit or
Seville oranges.
15. Use of heparin or warfarin during the trial.
16. Long-term treatment (> 2 weeks) before or during the trial with agents that have a
high risk for nephrotoxicity or hepatotoxicity.
1. Concomitant use (within 2 weeks of Day 1 and throughout trial conduct) of any
medications (prescription, OTC, herbal products) or foods as follows:
2. Known potent inhibitors of CYP3A, including statins (with the exception of
pravastatin and fluvastatin);
3. Known potent inducers of CYP3A or CYP3A sensitive substrates;
4. Known CYP2C19 and P-gp sensitive substrates with a narrow therapeutic index -
refer to the Concomitant Medication Manual for additional instructions;
5. Known sensitive substrates of OCT1 with a narrow therapeutic index; and
6. Drugs known to prolong the PR or QT interval unless otherwise described in this
protocol.
17. Concomitant use of medications contraindicated in the prescribing information for RTV.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
15/05/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
30/04/2025
Query!
Actual
Query!
Sample size
Target
30
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
Israel
Query!
State/province [1]
0
0
Be'er Sheva
Query!
Country [2]
0
0
New Zealand
Query!
State/province [2]
0
0
Auckland
Query!
Country [3]
0
0
Turkey
Query!
State/province [3]
0
0
Istanbul
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Soroka University Medical Center
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Eiger BioPharmaceuticals
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Open label, single arm, multi-center clinical trial of lonafarnib 50 mg QD plus ritonavir 200
mg QD, administered orally, over a 48-week treatment period, with a 24-week post-treatment
follow-up period, in patients with chronic Hepatitis D Virusinfection.
Objectives: To evaluate the safety and tolerability of once daily dosing of lonafarnib 50 mg
with ritonavir 200 mg over a 48-week treatment period.
To evaluate the effect of once daily dosing of lonafarnib 50 mg with ritonavir 200 mg over a
48-week treatment period with a 24-week post-treatment follow-up on HDV viral levels.
Trial population: Up to 30 patients with chronic HDV infection with detectable HDV RNA and
compensated liver disease.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05229991
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Ohad Etzion, MD
Query!
Address
0
0
Soroka University Medical Center
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05229991
Download to PDF